Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Loses One, Gains One In Oncology

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo has unveiled disappointing results for one pipeline molecule that has now been suspended for lung cancer, but has gained another for breast cancer as it continues to develop its oncology portfolio.

You may also be interested in...



Daiichi's Quizartinib Looks To Join Novartis' Rydapt In AML

Phase III results for Daiichi Sankyo's FLT3 targeting quizartinib are in, but it's unclear as yet how the data will affect a niche, targeted hematology/oncology market.

Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions

Daiichi Sankyo says it is “committed to a major transformation in oncology” as it prioritizes and pursues projects in this field under a new team leader, who chose to highlight unique antibody-drug conjugate technology and the acute myeloid leukemia franchise at a recent R&D Day in Tokyo.

Daiichi Presses On With Lead Pexidartinib Trial Despite Liver Toxicity

Daiichi Sankyo is to continue with a multinational Phase III trial for its novel candidate for tenosynovial giant cell tumor despite cases of liver toxicity, but has stopped enrolment short of target and modified the protocol.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC089575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel